47 research outputs found
Evaluation of two methods for counting residual leukocytes in leuko-reduced platelets: Nageotte's method and flow cytometry
No full textIntroduction: Leukoreduced (LR) blood components are used for the prevention of several transfusion adverse effects. Advancement in technology has led to newer methods to count residual leukocytes (rWBC) which miss detection on most standard automated hematology analyzers.
Materials and Methods: Samples from thirty eight platelet concentrates (prepared by Buffy-coat method) were randomly taken on the day of preparation for rWBC count using Nageotte's chamber and flowcytometer.
Results: The rWBC count on Nageotte's ranged from 2.5 WBC/μL to a maximum of 600 WBC/μL where as the flowcytometric count had a lowest of 1.97 WBC/μL to a highest of 740 WBC/μL. We found that the WBC counts using the Nageotte's method and flowcytometeric method are highly correlated. The concordance correlation coefficient or intraclass correlation coefficient which is a measure of reliability was 0.78
Conclusion: In view of the high concordance in correlation coefficient between the two methods, Nageotte's method could be skillfully performed for assessing leukoreduction in LR platelet concentrates of resource constrained blood banks of developing nations
Epidemiology of Ocular Manifestations in Autoimmune Disease
No full textThe global prevalence of autoimmune diseases is increasing. As a result, ocular complications, ranging from minor symptoms to sight-threatening scenarios, associated with autoimmune diseases have also risen. These ocular manifestations can result from the disease itself or treatments used to combat the primary autoimmune disease. This review provides detailed insights into the epidemiological factors affecting the increasing prevalence of ocular complications associated with several autoimmune disorders
Ocular disorders and associated drug development challenges: the current scenario
No full textVision is one of the most important human sense and hence eye diseases leading to impairment of vision have been the hot topic for drug delivery research lately. Diseases like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy and trachomatous trichiasis have been known for their potential of visual impairment as well as blindness. A vast amount of research has been done in understanding the pathophysiology, risk factors and drug development and drug delivery challenges associated with these diseases, but the clinical success achieved so far is very sparse. This leading to the requirements for the better understanding of the ocular diseases which can be translated to better drug delivery systems. The current review is formulated with the aims to provide a concise summary of these ocular disorders and to address the challenges in their drug development research
Yoga practice improves the body mass index and blood pressure: A randomized controlled trial
No full textOcular disorders and associated drug development challenges: the current scenario
No full textVision is one of the most important human sense and hence eye diseases leading to impairment of vision have been the hot topic for drug delivery research lately. Diseases like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy and trachomatous trichiasis have been known for their potential of visual impairment as well as blindness. A vast amount of research has been done in understanding the pathophysiology, risk factors and drug development and drug delivery challenges associated with these diseases, but the clinical success achieved so far is very sparse. This leading to the requirements for the better understanding of the ocular diseases which can be translated to better drug delivery systems. The current review is formulated with the aims to provide a concise summary of these ocular disorders and to address the challenges in their drug development research
CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective
No full textIn the original published article, Satoru Kawakita and Shahid Khan affiliations are swapped. Please find below the correct affiliations.D. K. SahelDepartment of PharmacyBirla Institute of Technology and Science-PilaniBITS-Pilani, Vidya Vihar, Pilani, Rajasthan 333031, IndiaL. K. Vora, D. Mishra, R. R. Singh ThakurSchool of PharmacyQueen's University Belfast97 Lisburn Road, Belfast BT9 7BL, UKE-mail: [email protected]. Saraswat, K. PatelCollege of Pharmacy & Health SciencesSt. John's UniversityQueens, NY11439, USAS. Sharma, S. KawakitaTerasaki Institute for Biomedical InnovationLos Angeles, CA 90064, USAJ. MonparaDepartment of Pharmaceutical SciencesUniversity of SciencesPhiladelphia, PA 19104, USAA. A. D'SouzaGraduate School of Pharmaceutical Sciences and School of PharmacyDuquesne UniversityPittsburgh, PA 15282, USAK. P. Tryphena, D. K. KhatriMolecular and Cellular Neuroscience LabDepartment of Pharmacology and ToxicologyNational Institute of Pharmaceutical Education and Research(NIPER)-HyderabadTelangana 500037, IndiaE-mail: [email protected]. KhanDepartment of Biomedical EngineeringUniversity of CaliforniaDavis, CA 95616, USAM. AzharResearch and Development Tata Medical and Diagnostics LimitedMumbai, Maharashtra 400001, India<br/
Safety, biodegradability, and biocompatibility considerations of long-acting drug delivery systems
No full textBiodegradation and biocompatibility are crucial for developing long-acting implantable drug delivery systems. Because of the prolonged biological residence of these implants, understanding of in vivo degradation and biocompatibility helps establish the commercial success of these implants. International Organization for Standardization has laid down various guidelines for the development and optimization of in vitro degradation studies. This chapter discusses multiple ISO guidelines and current research to understand the influence of different study parameters on biodegradation study. The chapter also summarizes the immunological consideration in the design and evaluation of long-acting implants.<br/
Vitreous humor: composition, characteristics and implication on intravitreal drug delivery
No full textPurpose: Intravitreal administration of drug molecules is one of the most common routes for treating posterior segment eye diseases. However, the properties of vitreous humour changes with the time. A number of ocular complications such as liquefaction of the vitreous humour, solidification of the vitreous humour in the central vitreous cavity and detachment of the limiting membrane due to the shrinking of vitreous humour are some of the factors that can drastically affect the efficacy of therapeutics delivered via intravitreal route. Although significant research has been conducted for studying the properties of vitreous humour and its changes during the ageing process, there have been limited work to understand the effect of these changes on therapeutic efficacy of intravitreal drug delivery systems. Therefore, in this review we discussed both the coomposition and characteristics of the vitreous humour, and their subsequent influence on intravitreal drug delivery.Methods: Articles were searched on Scopus, PubMed and Web of Science up to March 2022.Results: In this review, we discussed the biological composition and biomechanical properties of vitreous humour, methods to study the properties of vitreous humour and the changes in these properties and their relevance in ocular drug delivery field, with the aim to provide a useful insight into these aspects which can aid the process of development of novel intravitreal drug delivery systems.Conclusions: The composition and characteristics of the vitreous humour, and how these change during natural aging processes, directly influence intravitreal drug delivery. This review therefore highlights the importance of understanding the properties of the vitreous and identifies the need to achieve greater understanding of how changing properties of the vitreous affect the therapeutic efficacy of drugs administered for the treatment of posterior eye diseases
